Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magic mushroom therapy takes on meth addiction in veterans

NCT ID NCT04982796

Disease control Sponsor: Portland VA Research Foundation, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether psilocybin, the active ingredient in magic mushrooms, combined with psychotherapy can help veterans with moderate to severe methamphetamine use disorder. Thirty participants will receive either psilocybin-enhanced therapy or standard treatment. The study focuses on whether the approach is safe, acceptable, and feasible, not yet on proving it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
psilocybin
What this could lead to
If this works, it could point toward a new treatment option for methamphetamine use disorder, potentially helping people reduce or stop use.
What could go wrong
This is a very early, small proof-of-concept study with only 30 veterans. It primarily measures safety and feasibility, not effectiveness. Psilocybin may cause adverse events or not show benefit over usual care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * United States military Veteran * Moderate to severe methamphetamine use disorder using the DSM-V diagnostic criteria * Desire to cease or reduce methamphetamine use Exclusion Criteria: * Have uncontrolled hypertension or clinically significant cardiovascular disease * History of seizure disorder in adulthood * CNS metastases or symptomatic central nervous system (CNS) infection * Poorly controlled diabetes mellitus * Taking certain medications that may interact with psilocybin * History of any primary persistent psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, major depressive disorder with psychosis, or schizophreniform disorder * History of bipolar I disorder * Current eating disorder with active purging * History of hallucinogen use disorder * Pregnant or breast feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amphetamine-related disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amphetamine abuse methamphetamine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amphetamine-related disorders

Contacts and locations

Locations

  • Portland VA Health Care System

    Vancouver, Washington, 98661, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.